Fluorescence resonance energy transfer analysis of merlin conformational changes

Molecular and Cellular Biology

Volumn 30, Issue 1, 2010, Pages 54-67

  Hennigan, Robert F ^a,b   Foster, Lauren A ^a   Chaiken, Mary F ^a   Mani, Timmy ^a   Gomes, Michelle M ^a   Herr, Andrew B ^a   Ip, Wallace ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN; MONOMER;

ALPHA HELIX; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION;

ANIMALS; CELL LINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; MICE; MODELS, BIOLOGICAL; NEUROFIBROMIN 2; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SCHWANN CELLS; SODIUM-HYDROGEN ANTIPORTER;

EID: 73549124543     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00248-09     Document Type: Article

References (52)

1. Alfthan, K., L. Heiska, M. Gronholm, G. H. Renkema, and O. Carpen. 2004. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J. Biol. Chem. 279:18559-18566.
2. Alkaabi, K. M., A. Yafea, and S. S. Ashraf. 2005. Effect of pH on thermaland chemical-induced denaturation of GFP. Appl. Biochem. Biotechnol. 126:149-156.
3. Barret, C., C. Roy, P. Montcourrier, P. Mangeat, and V. Niggli. 2000. Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding site in the NH(2)-terminal domain of ezrin correlates with its altered cellular distribution. J. Cell Biol. 151:1067-1080.
4. Bretscher, A., D. Chambers, R. Nguyen, and D. Reczek. 2000. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu. Rev. Cell Dev. Biol. 16:113-143.
5. Burkhard, P., S. Ivaninskii, and A. Lustig. 2002. Improving coiled-coil stability by optimizing ionic interactions. J. Mol. Biol. 318:901-910.
6. Fievet, B. T., A. Gautreau, C. Roy, L. Del Maestro, P. Mangeat, D. Louvard, and M. Arpin. 2004. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J. Cell Biol. 164:653-659.
7. Giovannini, M., E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J. M. Woodruff, A. Berns, and G. Thomas. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14:1617-1630.
8. Gonzalez-Agosti, C., T. Wiederhold, M. E. Herndon, J. Gusella, and V. Ramesh. 1999. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J. Biol. Chem. 274:34438-34442.
9. Gronholm, M., M. Sainio, F. Zhao, L. Heiska, A. Vaheri, and O. Carpen. 1999. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J. Cell Sci. 112(6):895-904.
10. Hamada, K., T. Shimizu, T. Matsui, S. Tsukita, and T. Hakoshima. 2000. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J. 19:4449-4462.
11. Hamada, K., T. Shimizu, S. Yonemura, S. Tsukita, S. Tsukita, and T. Hakoshima. 2003. Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J. 22:502-514.
12. Hoeflich, K. P., S. Tsukita, L. Hicks, C. M. Kay, S. Tsukita, and M. Ikura. 2003. Insights into a single rod-like helix in activated radixin required for membrane-cytoskeletal cross-linking. Biochemistry 42:11634-11641.
13. Ishikawa, H., A. Tamura, T. Matsui, H. Sasaki, T. Hakoshima, S. Tsukita, and S. Tsukita. 2001. Structural conversion between open and closed forms of radixin: low-angle shadowing electron microscopy. J. Mol. Biol. 310:973-978.
14. Jin, H., T. Sperka, P. Herrlich, and H. Morrison. 2006. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442:576-579.
15. Kain, S. R., and P. Kitts. 1997. Expression and detection of green fluorescent protein (GFP). Methods Mol. Biol. 63:305-324.
16. Kang, B. S., D. R. Cooper, Y. Devedjiev, U. Derewenda, and Z. S. Derewenda. 2002. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr. D Biol. Crystallogr. 58:381-391.
17. Kim, H., J. Y. Lim, Y. H. Kim, H. Kim, S. H. Park, K. H. Lee, H. Han, S. S. Jeun, J. H. Lee, and H. K. Rha. 2002. Inhibition of ras-mediated activator protein 1 activity and cell growth by merlin. Mol. Cells 14:108-114.
18. Kissil, J. L., K. C. Johnson, M. S. Eckman, and T. Jacks. 2002. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277:10394-10399.
19. Kohn, W. D., C. M. Kay, and R. S. Hodges. 1997. Salt effects on protein stability: two-stranded alpha-helical coiled-coils containing inter- or intrahelical ion pairs. J. Mol. Biol. 267:1039-1052.
20. Li, Q., M. R. Nance, R. Kulikauskas, K. Nyberg, R. Fehon, P. A. Karplus, A. Bretscher, and J. J. Tesmer. 2007. Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J. Mol. Biol. 365:1446-1459.
21. Matsui, T., M. Maeda, Y. Doi, S. Yonemura, M. Amano, K. Kaibuchi, S. Tsukita, and S. Tsukita. 1998. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their headto-tail association. J. Cell Biol. 140:647-657.
22. McClatchey, A. I. 2003. Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer 3:877-883.
23. McClatchey, A. I., I. Saotome, K. Mercer, D. Crowley, J. F. Gusella, R. T. Bronson, and T. Jacks. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1121-1133.
24. McClatchey, A. I., I. Saotome, V. Ramesh, J. F. Gusella, and T. Jacks. 1997. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 11:1253-1265.
25. Mori, T., K. Kitano, S. Terawaki, R. Maesaki, Y. Fukami, and T. Hakoshima. 2008. Structural basis for CD44 recognition by ERM proteins. J. Biol. Chem. 283:29602-29612.
26. Morrison, H., L. S. Sherman, J. Legg, F. Banine, C. Isacke, C. A. Haipek, D. H. Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15:968-980.
27. Nagai, T., K. Ibata, E. S. Park, M. Kubota, K. Mikoshiba, and A. Miyawaki. 2002. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20:87-90.
28. Ng, T., M. Parsons, W. E. Hughes, J. Monypenny, D. Zicha, A. Gautreau, M. Arpin, S. Gschmeissner, P. J. Verveer, P. I. Bastiaens, and P. J. Parker. 2001. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. 20:2723-2741.
29. Nguyen, R., D. Reczek, and A. Bretscher. 2001. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J. Biol. Chem. 276:7621-7629.
30. Okada, M., Y. Wang, S. W. Jang, X. Tang, L. M. Neri, and K. Ye. 2009. Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res. 69:4043-4051.
31. Okada, T., M. Lopez-Lago, and F. G. Giancotti. 2005. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J. Cell Biol. 171:361-371.
32. Pearson, M. A., D. Reczek, A. Bretscher, and P. A. Karplus. 2000. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101:259-270.
33. Piston, D. W., and G. J. Kremers. 2007. Fluorescent protein FRET: the good, the bad and the ugly. Trends Biochem. Sci. 32:407-414.
34. Rizzo, M. A., G. H. Springer, B. Granada, and D. W. Piston. 2004. An improved cyan fluorescent protein variant useful for FRET. Nat. Biotechnol. 22:445-449.
35. Rong, R., E. I. Surace, C. A. Haipek, D. H. Gutmann, and K. Ye. 2004. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 23:8447-8454.
36. Schuck, P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78:1606-1619.
37. Shaw, R. J., J. G. Paez, M. Curto, A. Yaktine, W. M. Pruitt, I. Saotome, J. P. O'Bryan, V. Gupta, N. Ratner, C. J. Der, T. Jacks, and A. I. McClatchey. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1:63-72.
38. Sherman, L., H. M. Xu, R. T. Geist, S. Saporito-Irwin, N. Howells, H. Ponta, P. Herrlich, and D. H. Gutmann. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509.
39. Shimizu, T., A. Seto, N. Maita, K. Hamada, S. Tsukita, S. Tsukita, and T. Hakoshima. 2002. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J. Biol. Chem. 277:10332-10336.
40. Shimozono, S., and A. Miyawaki. 2008. Engineering FRET constructs using CFP and YFP. Methods Cell Biol. 85:381-393.
41. Smith, J. S., and J. M. Scholtz. 1998. Energetics of polar side-chain interactions in helical peptides: salt effects on ion pairs and hydrogen bonds. Biochemistry 37:33-40.
42. Surace, E. I., C. A. Haipek, and D. H. Gutmann. 2004. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 23:580-587.
43. Terawaki, S., R. Maesaki, and T. Hakoshima. 2006. Structural basis for NHERF recognition by ERM proteins. Structure 14:777-789.
44. Terawaki, S., R. Maesaki, K. Okada, and T. Hakoshima. 2003. Crystallographic characterization of the radixin FERM domain bound to the Cterminal region of the human Na+/H+-exchanger regulatory factor (NHERF). Acta Crystallogr. D Biol. Crystallogr. 59:177-179.
45. Trofatter, J. A., M. M. MacCollin, J. L. Rutter, J. R. Murrell, M. P. Duyao, D. M. Parry, R. Eldridge, N. Kley, A. G. Menon, K. Pulaski, et al. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800.
46. Turunen, O., M. Sainio, J. Jaaskelainen, O. Carpen, and A. Vaheri. 1998. Structure-function relationships in the ezrin family and the effect of tumorassociated point mutations in neurofibromatosis 2 protein. Biochim. Biophys. Acta 1387:1-16.
47. Xiao, G. H., A. Beeser, J. Chernoff, and J. R. Testa. 2002. p21-activated kinase links Rac/Cdc42 signaling to merlin. J. Biol. Chem. 277:883-886.
48. Xu, H. M., and D. H. Gutmann. 1998. Merlin differentially associates with the microtubule and actin cytoskeleton. J. Neurosci. Res. 51:403-415.
49. Yonemura, S., T. Matsui, S. Tsukita, and S. Tsukita. 2002. Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J. Cell Sci. 115:2569-2580.
50. Zhu, L., Y. Liu, and J. G. Forte. 2005. Ezrin oligomers are the membranebound dormant form in gastric parietal cells. Am. J. Physiol. Cell Physiol. 288:C1242-1254.
51. Zhu, L., R. Zhou, S. Mettler, T. Wu, A. Abbas, J. Delaney, and J. G. Forte. 2007. High turnover of ezrin T567 phosphorylation: conformation, activity, and cellular function. Am. J. Physiol. Cell Physiol. 293:C874-C884.
52. Zwicker, N., K. Adelhelm, R. Thiericke, S. Grabley, and F. Hanel. 1999. Strep-tag II for one-step affinity purification of active bHLHzip domain of human c-Myc. BioTechniques 27:368-375.